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Conclusions
• Abundant cell invasion and migration through the brain parenchyma is a
hallmark of GBM.
• In the brain, GBM cell invasion can be regulated by cell volume changes.
Cell volume dynamics can facilitate invasion and regulate cell division.
• SPAK and OSR1 are members of the STE20 superfamily of MAPK
kinases. These kinases are master regulators of cell volume regulation.
• We decided to study their implication in GBM malignancy by targeting
their activity using small molecule inhibitors. Specifically we want to
investigate if radiation treatment in combination with SPAK/OSR1
inhibition has synergistic effects.
Background
Abstract
Cell Proliferation of  120,612 and 965 GBM cell lines using Yu566 
indifferent concentrations in combination with radiation.  
The clonogenecity of 965 GBM cells after the treatment of 1uM 
YU566 followed by radiation. 
Glioblastoma (GBM) is the most aggressive brain tumor in
adults. Cell invasion, migration and proliferation into the
heathy brain parenchyma it’s one of the most important
challenges in the treatment of this deadly tumor. One potential
mechanism that GBM cells can utilize to enhance cell
migration and evade pro-apoptotic signals is the tight
regulation of cell volume by the STE20/SPS1-Related Proline-
Alanine-Rich Protein Kinase (SPAK) and (Oxidative Stress
Responsive Kinase 1) OSR1 kinases. Dynamic changes in cell
volume can be used by GBM cells to disseminate through the
narrow perivascular spaces of the brain. In addition, cancer
cells could counteract pro-apoptotic reduction of cell volume
by increasing the activity of these kinases. The objective of
this project is to test the efficacy of SPAK and OSR1 inhibition
alone or in combination with radiotherapy. For this purpose we
evaluated the impact of this novel therapy on the proliferation,
clonogenicity and apoptosis of primary patient-derived GBM
cells in vitro. To achieve our goal we tested a novel
SPAK/OSR1 inhibitor (a small molecule called YU566) in two
patient derived GBM lines. Cell proliferation and colony
formation were determined after treatment using 1uM YU566
alone or in combination with radiotherapy (at different doses 2,
4 Gray (Gy)). We found that radiation and inhibition of
SPAK/OSR1 could act in a synergistic fashion, decreasing cell
proliferation and clonogenic potential. The next steps in our
research will be to determine the mechanisms of cell death
and the implications of this therapy in vivo.
Methodology and Statistics
Cell proliferation was measured using Cyquant assay after combined treatment of
radiotherapy and inhibition of SPAK/OSR1. YU566 was added to the cells for 24 hours
followed by radiation for 72 hours in three GBM cell lines: 612, 120, and 965. (Figure
2). A parametric one way-ANOVA, was then run to determine significance. Dunnett’s
test was then run in order to do a multiple comparison between the different
treatments. All treatment groups were compared to the control.
Colony formation was measured to determine clonogenecity after 15 days of treatment.
1 uM of inhibitor YU566 was added for 24 hours followed by radiation for 72 hours.
This tested the capability of cell growth clones. The effects were then observed and
measured after 15 days after treatment where the number of colonies were counted
(Figure 1).
Colony formation was again tested however by radiation first for 72 hours followed by 1
uM of the inhibitor YU566 for 48 hours. This was done to determine if the order of
radiotherapy versus inhibition of SPAK/ OSR1 first resulted in a shift in results. Cell
clonogenicity was measured again after 15 days of treatment (Figure 3).
Figure 2. Cell proliferation of GBM cells using YU566 inhibitor in combination with radiation
treatment using three cell GBM lines: 120, 612 and 965. The upper panel consisted of .25 uM
YU566 while the lower panel consisted of 1 uM YU566. Bar graph represent mean plus SEM, all
groups are compared to non-treated control. ****p<0.0001 ***p=0.0002 **p=0.0021 *p=0.0332.
Figure 1. Clonogenecity of 965 GBM cells after the treatment of 1uM YU566 for 24 hours
followed by radiation after 72 hours. The different treatment groups are shown as control,
YU566, Radiation and the combination of both. The graph on the left reveals radiation at 2 Gy.
The graph on the right reveals 4Gy radiation treatment. Combination treatment of 2Gy + YU566
p=0.0137; Combination treatment of 4Gy + YU566 p=0.0065.
Figure 3. Clonogenecity of 965 GBM cells after treatment of radiation first at 2 Gy shown on the left versus 4
Gy on the right followed by inhibition via 1 uM of YU566. The different treatment groups are shown as
control, YU566, Radiation and the combination of both. The graph on the left reveals radiation at 2 Gy, the
graph on the right reveals 4Gy radiation treatment. p= 0.0332, p=0.0142, respectively.
Glioblastoma (GBM) is the most aggressive brain tumor in adults. The five-year survival rate
for GBM is less than three percent and is mostly attributed to GBM’s ability to uncontrollably
proliferate along with its aforementioned ability to infiltrate into brain tissue necessary for
survival that is not able to be surgically removed. After the use of statistical tests, a significant
decrease in proliferation was found when the treatment consisted of inhibition and radiation in
combination. The different cell lines revealed different percent differences; however, the
pattern was the same in all cell lines for the reduction of cell proliferation. The chologenicity
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